Evofem Biosciences Future Growth
Future criteria checks 5/6
Evofem Biosciences is forecast to grow earnings and revenue by 60% and 36.9% per annum respectively while EPS is expected to grow by 58.4% per annum.
Key information
60.0%
Earnings growth rate
58.4%
EPS growth rate
Pharmaceuticals earnings growth | 20.1% |
Revenue growth rate | 36.9% |
Future return on equity | n/a |
Analyst coverage | Low |
Last updated | n/a |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2025 | 193 | 24 | N/A | N/A | 1 |
12/31/2024 | 125 | -17 | N/A | N/A | 1 |
12/31/2023 | 73 | -48 | N/A | N/A | 2 |
12/31/2022 | 32 | -199 | N/A | N/A | 2 |
6/30/2022 | 16 | -283 | -107 | -106 | N/A |
3/31/2022 | 11 | -192 | -135 | -133 | N/A |
12/31/2021 | 8 | -206 | -150 | -147 | N/A |
9/30/2021 | 5 | -194 | -169 | -164 | N/A |
6/30/2021 | 3 | -150 | -167 | -163 | N/A |
3/31/2021 | 2 | -169 | -128 | -124 | N/A |
12/31/2020 | 0 | -142 | -107 | -105 | N/A |
9/30/2020 | 0 | -114 | -80 | -79 | N/A |
6/30/2020 | N/A | -98 | -58 | -58 | N/A |
3/31/2020 | N/A | -81 | -63 | -62 | N/A |
12/31/2019 | N/A | -80 | -55 | -55 | N/A |
9/30/2019 | N/A | -82 | -52 | -52 | N/A |
6/30/2019 | N/A | -87 | -46 | -46 | N/A |
3/31/2019 | N/A | -75 | -46 | -46 | N/A |
12/31/2018 | N/A | -126 | -57 | -56 | N/A |
9/30/2018 | N/A | -131 | -51 | -51 | N/A |
6/30/2018 | N/A | -188 | -47 | -47 | N/A |
3/31/2018 | N/A | -172 | -31 | -31 | N/A |
12/31/2017 | N/A | -109 | -19 | -19 | N/A |
9/30/2017 | N/A | -103 | -20 | -20 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 1AQ is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (0.03%).
Earnings vs Market: 1AQ is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: 1AQ is expected to become profitable in the next 3 years.
Revenue vs Market: 1AQ's revenue (36.9% per year) is forecast to grow faster than the German market (4.6% per year).
High Growth Revenue: 1AQ's revenue (36.9% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if 1AQ's Return on Equity is forecast to be high in 3 years time